Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
35.00
-0.12 (-0.34%)
At close: Jun 16, 2026, 4:00 PM EDT
35.10
+0.10 (0.29%)
Pre-market: Jun 17, 2026, 5:16 AM EDT

Crinetics Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Crinetics Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $83.14. The average 1-year stock price forecast is 137.54% higher than the current stock price, while the lowest is $55 (+57.14%) and the highest is $97 (+177.14%).

Price Target: $83.14 (+137.54%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$55$83.14$86$97
Change+57.14%+137.54%+145.71%+177.14%

Analyst Ratings

The average analyst rating for Crinetics Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy111212121212
Buy333333
Hold111111
Sell000000
Strong Sell000000
Total151616161616

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Leerink Partners
Leerink Partners
Buy
Maintains
$95
BuyMaintains$95+171.43%Jun 11, 2026
Evercore ISI
Evercore ISI
Buy
Reiterates
$89$88
BuyReiterates$89$88+151.43%May 15, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$87$84
BuyMaintains$87$84+140.00%May 11, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$97
BuyMaintains$97+177.14%May 8, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Maintains
$83
BuyMaintains$83+137.14%May 8, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
68.55M
from 7.70M
Increased by 790.73%
Revenue Next Year
173.02M
from 68.55M
Increased by 152.40%
EPS This Year
-4.78
from -4.95
EPS Next Year
-4.21
from -4.78
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.08M4.74M4.01M1.04M7.70M68.55M
Revenue Growth
1,418.31%339.43%-15.28%-74.11%640.71%790.73%
Gross Profit
-83.18M-125.49M-164.51M-239.12M-325.44M64.30M
Gross Margin
-7,715.86%-2,649.10%-4,099.53%-23,014.15%-4,228.66%93.80%
Operating Income
-107.70M-167.88M-222.61M-338.85M-516.77M-547.09M
Net Income
-107.64M-163.92M-214.53M-298.41M-465.32M-511.63M
EPS
-----4.95-4.78
Free Cash Flow
-48.47M-62.51M-93.53M-136.41M-206.91M-417.67M
No. Analysts
-----13
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High76.1M
Avg68.6M
Low57.7M

Revenue Growth

Revenue Growth202620272028
High
888.6%
Avg
790.7%
Low
650.2%

EPS Forecast

EPS202620272028
High-3.87
Avg-4.78
Low-5.25

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-